Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Sacco · SciRah

Researcher profile · Semantic Scholar

C. Sacco

Share profile

C. Sacco — researcher profile on SciRah

h-index: 24
Works: 119
Citations: 3,266

Most-cited papers

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
C. Gridelli, F. Perrone, C. Gallo, S. Cigolari +19 more
2003Journal of the National Cancer Institute781 citations Open access
Semantic Scholar
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.
P. Maione, F. Perrone, C. Gallo, L. Manzione +130 more
2005Journal of Clinical Oncology460 citations
Semantic Scholar
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
S. Pignata, G. Scambia, D. Katsaros, C. Gallo +26 more
2014The Lancet Oncology369 citations
Semantic Scholar
Taxane-induced nail changes: incidence, clinical presentation and outcome.
A. Minisini, A. Tosti, A. Sobrero, M. Mansutti +3 more
2003Annals of Oncology167 citations Open access
Semantic Scholar
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
A. Necchi, L. Mariani, N. Zaffaroni, L. Schwartz +14 more
2012The Lancet Oncology134 citations
Semantic Scholar
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
S. Pignata, G. Scambia, A. Bologna, S. Signoriello +24 more
2017Journal of Clinical Oncology70 citations
Semantic Scholar
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci +6 more
2011British Journal of Cancer70 citations Open access
Semantic Scholar
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
F. Donskov, Wan-Ling Xie, Anders Overby, J. Wells +17 more
2020European Urology Oncology61 citations Open access
Semantic Scholar
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
R. Iacovelli, G. Cartenì, C. Sternberg, M. Milella +20 more
2013European Journal of Cancer61 citations
Semantic Scholar
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets.
A. Caliò, M. Brunelli, D. Segala, S. Pedron +18 more
2020Pathology (Sydney)46 citations
Semantic Scholar
Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer.
A. Londero, M. Orsaria, G. Tell, S. Marzinotto +5 more
2014American Journal of Clinical Pathology46 citations Open access
Semantic Scholar
Unplanned presentations of cancer outpatients: a retrospective cohort study
G. Aprile, Federica Edith Pisa, A. Follador, L. Foltran +6 more
2013Supportive Care in Cancer46 citations
Semantic Scholar
Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.
A. Brunello, U. Basso, C. Sacco, T. Sava +7 more
2013Annals of Oncology43 citations Open access
Semantic Scholar
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
R. Iacovelli, U. de Giorgi, L. Galli, P. Zucali +19 more
2018Clinical Genitourinary Cancer32 citations
Semantic Scholar
Docetaxel, with or without estramustine phosphate, as first‐line chemotherapy for hormone‐refractory prostate cancer: results of a multicentre, randomized phase II trial
O. Caffo, T. Sava, E. Comploj, A. Fariello +6 more
2008BJU International32 citations
Semantic Scholar
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
U. de Giorgi, E. Scarpi, C. Sacco, M. Aieta +15 more
2014Clinical Genitourinary Cancer29 citations
Semantic Scholar
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci +6 more
2013Annals of Oncology27 citations Open access
Semantic Scholar
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
S. Pignata, G. Scambia, D. Lorusso, U. de Giorgi +27 more
2019Gynecologic Oncology26 citations Open access
Semantic Scholar
Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)
F. Esposito, S. Cecere, F. Magazzino, D. Katsaros +16 more
2014Oncology25 citations
Semantic Scholar
Impact of docetaxel‐based chemotherapy on quality of life of patients with castration‐resistant prostate cancer: results from a prospective phase II randomized trial
O. Caffo, T. Sava, E. Comploj, A. Fariello +5 more
2011BJU International25 citations
Semantic Scholar
Prognostic evaluation in palliative care: final results from a prospective cohort study
P. Ermacora, M. Mazzer, M. Isola, G. Pascoletti +13 more
2018Supportive Care in Cancer23 citations
Semantic Scholar
A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynec
S. Pignata, G. Scambia, R. Lauria, F. Raspagliesi +16 more
2013Journal of Clinical Oncology22 citations
Semantic Scholar
Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey
V. Zagonel, R. Torta, V. Franciosi, A. Brunello +24 more
2016Journal of Cancer21 citations Open access
Semantic Scholar
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.
Giorgio Mustacchi, M. Mansutti, C. Sacco, S. Barni +4 more
2009Annals of Oncology21 citations Open access
Semantic Scholar
Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care)
V. Zagonel, V. Franciosi, A. Brunello, G. Biasco +28 more
2017Tumori20 citations Open access
Semantic Scholar
Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties.
F. Grossi, O. Belvedere, G. Fasola, T. Ceschia +8 more
2004Journal of Clinical Epidemiology18 citations
Semantic Scholar
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy
A. Necchi, M. Pennati, N. Zaffaroni, E. Landoni +17 more
2013British Journal of Cancer17 citations Open access
Semantic Scholar
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
R. Iacovelli, A. Farcomeni, C. Sternberg, G. Cartenì +22 more
2015Journal of Urology14 citations
Semantic Scholar
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M. Piccirillo, G. Scambia, A. Bologna, S. Signoriello +24 more
2018Annals of Oncology12 citations Open access
Semantic Scholar
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
O. Caffo, G. Lo Re, T. Sava, S. Buti +14 more
2015Future Oncology11 citations
Semantic Scholar
Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC).
A. Necchi, N. Nicolai, C. Ortega, T. Sava +9 more
2011Journal of Clinical Oncology11 citations
Semantic Scholar
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
S. Bracarda, L. Galli, M. Maruzzo, G. Lo Re +17 more
2018Future Oncology10 citations
Semantic Scholar
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica.
G. Banna, N. Nicolai, G. Palmieri, M. Ottaviano +38 more
2019Critical reviews in oncology/hematology8 citations Open access
Semantic Scholar
A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci +6 more
2016Journal of Clinical Oncology8 citations
Semantic Scholar
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
F. Grossi, G. Fasola, C. Rossetto, R. Spizzo +10 more
2006Lung Cancer8 citations
Semantic Scholar
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
S. Bianchi, A. Mosca, Alberto Dalla Volta, V. Prati +20 more
2021European Journal of Cancer7 citations Open access
Semantic Scholar
Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study.
A. Brunello, U. Basso, C. Sacco, T. Sava +7 more
20137 citations Open access
Semantic Scholar
Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)
O. Caffo, E. Palesandro, F. Nolè, D. Gasparro +16 more
2019Annals of Oncology6 citations
Semantic Scholar
Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program.
M. Cirillo, L. Carlucci, L. Legramandi, E. Baldini +23 more
2019Journal of Clinical Nursing5 citations
Semantic Scholar
Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized phase II trial (ATOM 017).
E. Rijavec, O. Belvedere, Marianna Aita, C. Rossetto +6 more
20105 citations
Semantic Scholar
IMPACT OF DOCETAXEL (D) – BASED CHEMOTHERAPY ON QUALITY OF LIFE (QOL) OF PATIENTS (PTS) WITH HORMONE- REFRACTORY PROSTATE CANCER (HRPC): RESULTS FROM A RANDOMISED PHASE II TRIAL WITH D ± ESTRAMUSTINE (E)
O. Caffo, T. Sava, E. Comploj, Z. Zustovich +6 more
20084 citations
Semantic Scholar
A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC).
O. Caffo, T. Sava, E. Comploj, A. Fariello +7 more
2006Journal of Clinical Oncology4 citations
Semantic Scholar
Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years.
S. Monfardini, A. Brunello, A. Molino, C. Sacco +6 more
2006Journal of Clinical Oncology4 citations
Semantic Scholar
Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci +6 more
20103 citations
Semantic Scholar
Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 007).
F. Grossi, O. Belvedere, C. Rossetto, A. Sibau +6 more
2004Journal of Clinical Oncology3 citations
Semantic Scholar
P-29 Phase II study of irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC) patients: preliminary results. An Alpe Adria thoracic oncology multidisciplinary group study (ATOM 007)
G. Fasola, O. Belvedere, R. Spizzo, Angela Sibau +6 more
20033 citations
Semantic Scholar
Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.
R. Iacovelli, S. Buti, C. Buttigliero, R. de Vivo +16 more
20202 citations
Semantic Scholar
D01*MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer
M. Piccirillo, G. Scambia, D. Lorusso, U. de Giorgi +16 more
20152 citations Open access
Semantic Scholar
Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).
E. Verzoni, R. Iacovelli, M. Rizzo, A. Felici +16 more
2013Journal of Clinical Oncology2 citations
Semantic Scholar
Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci +6 more
2013Journal of Clinical Oncology2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Sava×13
Invite
T. Sava — researcher profile on SciRah
G. Procopio×10
Invite
G. Procopio — researcher profile on SciRah
F. Perrone×8
Invite
F. Perrone — researcher profile on SciRah
S. Cinieri×8
Invite
S. Cinieri — researcher profile on SciRah

×7

Invite

C. Gallo — researcher profile on SciRah

Invite

O. Caffo — researcher profile on SciRah

Invite

S. Pignata — researcher profile on SciRah

Invite

V. Salutari — researcher profile on SciRah

Invite

C. Ortega — researcher profile on SciRah

Invite

E. Verzoni — researcher profile on SciRah

Invite

C. Porta — researcher profile on SciRah

Invite

G. Fasola — researcher profile on SciRah